Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,987 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effects of a Gly16Arg ADRB2 polymorphism on responses to salmeterol or montelukast in Japanese patients with mild persistent asthma.
Konno S, Hizawa N, Makita H, Shimizu K, Sakamoto T, Kokubu F, Saito T, Endo T, Ninomiya H, Iijima H, Kaneko N, Ito YM, Nishimura M; J-Blossom Study Group. Konno S, et al. Among authors: endo t. Pharmacogenet Genomics. 2014 May;24(5):246-55. doi: 10.1097/FPC.0000000000000043. Pharmacogenet Genomics. 2014. PMID: 24681963 Clinical Trial.
Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.
Nakamura H, Satoh H, Kaburagi T, Nishimura Y, Shinohara Y, Inagaki M, Endo T, Saito T, Hayashihara K, Hizawa N, Kurishima K, Nawa T, Kagohashi K, Kishi K, Ishikawa H, Ichimura H, Hashimoto T, Sato Y, Sakai M, Kamiyama K, Matsumura T, Unoura K, Furukawa K. Nakamura H, et al. Among authors: endo t. Med Oncol. 2012 Dec;29(5):3202-6. doi: 10.1007/s12032-012-0318-5. Epub 2012 Nov 2. Med Oncol. 2012. PMID: 23117478
Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group.
Kurishima K, Satoh H, Kaburagi T, Nishimura Y, Shinohara Y, Inagaki M, Endo T, Saito T, Hayashihara K, Hizawa N, Nakamura H, Nawa T, Kagohashi K, Kishi K, Ishikawa H, Ichimura H, Hashimoto T, Sato Y, Sakai M, Kamiyama K, Matsumura T, Unoura K, Fukuoka T, Uchiumi K, Nomura A, Furukawa K. Kurishima K, et al. Among authors: endo t. Mol Clin Oncol. 2013 Sep;1(5):828-832. doi: 10.3892/mco.2013.154. Epub 2013 Jul 23. Mol Clin Oncol. 2013. PMID: 24649255 Free PMC article.
[FACTORS ASSOCIATED WITH THE PRESENCE OF ALLERGEN-SPECIFIC IgE RESPONSES IN ASTHMA PATIENTS WHO HAD NO IgE RESPONSES DETECTABLE BY MAST-26].
Iijima H, Kaneko Y, Masuko H, Yamada H, Yatagai Y, Sakamoto T, Kanemoto K, Ishikawa H, Saito T, Endo T, Ninomiya H, Nomura A, Kodama T, Kaneko N, Kokubu F, Makita H, Konno S, Nishimura M, Hizawa N. Iijima H, et al. Among authors: endo t. Arerugi. 2015 Sep;64(9):1242-53. doi: 10.15036/arerugi.64.1242. Arerugi. 2015. PMID: 26657911 Japanese.
S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.
Inagaki M, Shinohara Y, Kaburagi T, Endo T, Homma S, Hizawa N, Kishi K, Nakamura H, Hayashihara K, Saito T, Kurishima K, Ishikawa H, Ichimura H, Nawa T, Kikuchi N, Miyazaki K, Kodama T, Satoh H, Furukawa K. Inagaki M, et al. Among authors: endo t. Mol Clin Oncol. 2016 Jun;4(6):1025-1030. doi: 10.3892/mco.2016.826. Epub 2016 Mar 21. Mol Clin Oncol. 2016. PMID: 27284438 Free PMC article.
Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.
Kaburagi T, Kiyoshima M, Nawa T, Ichimura H, Saito T, Hayashihara K, Yamada H, Satoh H, Endo T, Inage Y, Saito K, Inagaki M, Hizawa N, Sato Y, Ishikawa H, Sakai M, Kamiyama K, Kikuchi N, Nakamura H, Furukawa K, Kodama T, Yamashita T, Nomura A, Yoshida S. Kaburagi T, et al. Among authors: endo t. Anticancer Res. 2018 May;38(5):3145-3150. doi: 10.21873/anticanres.12577. Anticancer Res. 2018. PMID: 29715155
Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.
Yamada Y, Tamura T, Yamamoto Y, Ichimura H, Hayashihara K, Saito T, Yamada H, Endo T, Nakamura R, Inage Y, Satoh H, Iguchi K, Saito K, Inagaki M, Kikuchi N, Kurishima K, Ishikawa H, Sakai M, Kamiyama K, Shiozawa T, Hizawa N, Sekine I, Sato Y, Funayama Y, Miyazaki K, Kodama T, Hayashi S, Nomura A, Nakamura H, Furukawa K, Yamashita T, Okubo H, Suzuki H, Kiyoshima M, Kaburagi T. Yamada Y, et al. Among authors: endo t. Anticancer Res. 2020 Oct;40(10):5757-5764. doi: 10.21873/anticanres.14592. Anticancer Res. 2020. PMID: 32988903 Clinical Trial.
Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer.
Shiozawa T, Numata T, Tamura T, Endo T, Kaburagi T, Yamamoto Y, Yamada H, Kikuchi N, Saito K, Inagaki M, Kurishima K, Funayama Y, Miyazaki K, Koyama N, Furukawa K, Nakamura H, Kikuchi S, Ichimura H, Sato Y, Sekine I, Satoh H, Hizawa N. Shiozawa T, et al. Among authors: endo t. Anticancer Res. 2022 May;42(5):2583-2590. doi: 10.21873/anticanres.15736. Anticancer Res. 2022. PMID: 35489768
Variations in S100A8/A12 Gene Expression Are Associated with the Efficacy of Nintedanib and Acute Exacerbation Development in Idiopathic Pulmonary Fibrosis Patients.
Arai N, Nakajima M, Matsuyama M, Matsumura S, Yazaki K, Sakai C, Nonaka M, Yanai H, Numata T, Yamamoto Y, Akatsu Y, Iijima H, Morishima Y, Matsuno Y, Endo T, Muratani M, Ishii Y, Saito T, Hizawa N. Arai N, et al. Among authors: endo t. Am J Respir Cell Mol Biol. 2023 Aug;69(2):242-246. doi: 10.1165/rcmb.2023-0054LE. Am J Respir Cell Mol Biol. 2023. PMID: 37526393 No abstract available.
3,987 results